Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 8:10:1297900.
doi: 10.3389/fcvm.2023.1297900. eCollection 2023.

Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results

Jiří Plášek  1   2 , Jozef Dodulík  1 , Marie Lazárová  1 , David Stejskal  3   4 , Zdeněk Švagera  3   4 , Nela Chobolová  3 , Patrik Šulc  1 , Lukáš Evin  1   2 , Dana Purová  5 , Jan Václavík  1   2
Affiliations

Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results

Jiří Plášek et al. Front Cardiovasc Med. .

Erratum in

Abstract

Background: Secretoneurin (SN) is a neuropeptide with potential utility as a biomarker of cardiovascular episodes. The main effect of SN is mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences calcium handling. We aimed to associate the levels of SN in plasma with different causes of heart failure.

Methods: We prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. SN was analysed from venous blood by use of the ELISA method. SN plasma levels were compared in DCM, ICM and healthy individuals with non-parametric tests.

Results: A total of 53 patients (81.1% male, 18.9% female; mean age 67.9 ± 12.6 years) and 34 healthy individuals (38% male, 62% female) were included in the analysis. Plasma SN levels were significantly higher in the dilated cardiomyopathy (38.8 ± 27 pmol/L) as compared with the ischaemic cardiomyopathy (19.7 ± 22.6 pmol/L) group (P = 0.006). There was no significant difference between females vs. males (27.1 ± 23 vs. 25.5 ± 26.2 pmol/L, P = NS). Plasma SN levels allowed DCM and ICM to be differentiated with 88% sensitivity and 61% specificity (P = 0.007), the cut of value is 13.3 pmol/L. Plasma SN levels differed significantly between healthy volunteers and both ICM (P < 0.0001) and DCM (P = 0.049). Plasma SN levels did not differ according to age and were not associated with comorbidities, left ventricular ejection fraction, heart failure medication, troponin, creatinine, or natriuretic peptide plasma levels.

Conclusion: Plasma secretoneurin levels differed significantly in DCM vs. ICM, being higher in the former. Based on plasma SN levels, discrimination between DCM and ICM might be possible. Healthy individuals produce higher SN plasma levels than stable HFrEF patients.

Keywords: CaMKII; dilated cardiomyopathy; heart failure; ischaemic cardiomyopathy; secretoneurin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Box-plot with whiskers displaying differences in SN plasma level between ICM and DCM. The red dots stand for individual measurement value. Secretoneurin (SN) plasma levels in pmol/L according to the cause of heart failure; ICM, ischaemic cardiomyopathy; DCM, dilated cardiomyopathy.
Figure 2
Figure 2
Receiver operating curve (ROC) for secretoneurin (SN, green curve), high-sensitivity troponin I (hs-TnI, blue curve) and N-terminal-pro natriuretic peptide (NT-pro-BNP, red curve) differentiating dilated cardiomyopathy from ischaemic cardiomyopathy (SN, AUC 0.73, 95% CI 0.58–0.87, P = 0.007; TnI, AUC 0.56, 95% CI 0.4–0.73, P = NS;NT-pro-BNP, AUC 0.44, 95% CI 0.27–0.62, P = NS).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Anderson ME. Will secretoneurin be the next big thing. J Am Coll Cardiol. (2015) 65(4):352–4. 10.1016/j.jacc.2014.11.028 - DOI - PubMed
    1. Plášek J, Lazárová M, Dodulík J, Šulc P, Stejskal D, Švagera Z, et al. Secretoneurin as a novel biomarker of cardiovascular episodes: are we there yet? A narrative review. J Clin Med. (2022) 11(23):7191. 10.3390/jcm11237191 - DOI - PMC - PubMed
    1. Ottesen AH, Louch WE, Carlson CR, Landsverk OJB, Kurola J, Johansen RF, et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. (2015) 65:339–51. 10.1016/j.jacc.2014.10.065 - DOI - PubMed
    1. Luo M, Anderson ME. Mechanisms of altered Ca2+ handling in heart failure. Circ Res. (2013) 113(6):690–708. 10.1161/CIRCRESAHA.113.301651 - DOI - PMC - PubMed
    1. Røsjø H, Meessen J, Ottesen AH, Latini R, Omland T, GISSI HF investigators. Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-heart failure trial. Clin Biochem. (2023) 118:110595. 10.1016/j.clinbiochem.2023.110595 - DOI - PubMed